```
* * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:52:19 ON 22 SEP 2004

=> file reg

=>
Uploading 10715794.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 full
L3            0 SEA SSS FUL L1

=>
Uploading 10715794.str

L4      STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4              STR
```



G1 H,Me,Et

G2 Ph

G3 O,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l4 full
L5          309 SEA SSS FUL L4

=> file ca

=> s l5
L6          121 L5

=> s l6 and py<2002
      20908594 PY<2002
L7          40 L6 AND PY<2002

=> d ibib abs fhitstr 1-40
```

L7 ANSWER 1 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 137:87967 CA
TITLE: Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer
AUTHOR(S): Kelland, Lloyd R.; Smith, Vicki; Valenti, Melanie; Patterson, Lisa; Clarke, Paul A.; Detre, Simone; End, Dave; Howes, Angela J.; Dowsett, Mitch; Workman, Paul; Johnston, Stephen R. D.
CORPORATE SOURCE: CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, Surrey, SM2 5NG, UK
SOURCE: Clinical Cancer Research (2001), 7(11), 3544-3550
CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Antitumor and pharmacodynamic studies were performed in MCF-7 human breast cancer cells and companion xenografts with the farnesyl protein transferase inhibitor, R115777, presently undergoing Phase II clin. trials, including in breast cancer. R115777 inhibited the growth of MCF-7 cells in vitro with an IC50 of 0.31 .+-. 0.25 .mu.M. Exposure of MCF-7 cells to increasing concns. of R115777 for 24 h resulted in the inhibition of protein farnesylation, as indicated by the appearance of prelamin A at concns. >1 .mu.M. After continuous exposure to 2 .mu.M R115777, prelamin A levels peaked at 2 h post drug exposure and remained high for up to 72 h. R115777 administered orally twice daily for 10 consecutive days to mice bearing established s.c. MCF-7 xenografts induced tumor inhibition at a dose of 25 mg/kg [percentage of treated vs. control (% T/C) = 63% at day 21]. Greater inhibition was obsd. at doses of 50 mg/kg (% T/C at day 21 = 38%) or 100 mg/kg (% T/C at day 21 = 43%). The antitumor effect appeared to be mainly cytostatic with little evidence of tumor shrinkage to less than the starting vol. Tumor response correlated with an increase in the appearance of prelamin A, but no changes in the prenylation of lamin B, heat-shock protein 40, or N-Ras were detectable. In addn., significant increases in apoptotic index and p21WAF1/CIP1 expression were obsd., concomitant with a decrease in proliferation as measured by Ki-67 staining. An increase in prelamin A was also obsd. in peripheral blood lymphocytes in a breast cancer patient who responded to R115777. These data show that R115777 possesses preclin. antitumor activity against human breast cancer and that the appearance of prelamin A may provide a sensitive and convenient pharmacodynamic marker of inhibition of prenylation and(or) response.
IT **192185-68-5**, R115777
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preclin. antitumor activity and pharmacodynamic studies with farnesyl protein transferase inhibitor R115777 in human breast cancer)

L7 ANSWER 1 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)
RN 192185-68-5 CA
CN 2(1H)-Quinolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 136:160732 CA
TITLE: Current status of clinical trials of farnesyltransferase inhibitors
AUTHOR(S): Karp, Judith E.; Kaufmann, Scott H.; Adjei, Alex A.; Lancet, Jeffrey E.; Wright, John J.; End, David W.
CORPORATE SOURCE: University of Maryland Greenebaum Cancer Center, Baltimore, MD, 21201, USA
SOURCE: Current Opinion in Oncology (2001), 13(6), 470-476
CODEN: CUOOE8; ISSN: 1040 8746
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Farnesyltransferase inhibitors represent a new class of agents that target signal transduction pathways responsible for the proliferation and survival of diverse malignant cell types. Although these agents were developed to prevent a processing step necessary for membrane attachment and maturation of Ras proteins, recent studies suggest that farnesyltransferase inhibitors block the farnesylation of addnl. cellular polypeptides, thereby exerting antitumor effects independent of the presence of activating ras gene mutations. Clin. trials of two farnesyltransferase inhibitors the tricyclic SCH66336 and the methylquinolone R115777-as single agents have demonstrated disease stabilization or objective responses in 10 to 15% of patients with refractory malignancies. Combinations of farnesyltransferase inhibitors with cytotoxic chemotherapies are yielding complete and partial responses in patients with advanced solid tumors. A phase I trial of R115777 in refractory and relapsed acute leukemias induced responses in 8 (32%) of 25 patients with acute myelogenous leukemia (including two complete remissions) and in two of three with chronic myelogenous leukemia in blast crisis. In patients with solid tumors, accessible normal tissues such as peripheral blood lymphocytes or, perhaps more germane to epithelial malignancies, buccal mucosa have provided surrogate tissues that allow confirmation that farnesyltransferase is inhibited in vivo at clin. achievable drug doses. In conjunction with the R115777 acute leukemia trial, serial measurements provided evidence of farnesyltransferase enzyme inhibition, interference with farnesyltransferase function (ie, protein processing), and blockade of signal transduction pathways in leukemic bone marrow cells. Preclin. studies of farnesyltransferase inhibitor resistance and clin. trials of farnesyltransferase inhibitors in combination with other agents currently are in progress.
IT **192185-68-5**, R115777
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyltransferase inhibitors in patients with malignancies)
RN 192185-68-5 CA
CN 2(1H) Quinolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 136:111921 CA
TITLE: R-115777. Oncolytic, farnesyl protein transferase inhibitor
AUTHOR(S): Sorbera, L. A.; Fernandez, R.; Castaner, J.
CORPORATE SOURCE: Prous Science, Barcelona, 08080, Spain
SOURCE: Drugs of the Future (2001), 26(5), 453-461
CODEN: DRFUD4; ISSN: 0377-8282
PUBLISHER: Prous Science
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review discusses the synthesis, pharmacol. actions, and clin. studies of R-115777. This compd. is an orally bioavailable, methyl-quinolone deriv. that is a selective nonpeptidomimetic inhibitor of farnesyl protein transferase. It has exhibited potent in vivo and in vitro activity.

IT **192185-68-5**, R-115777
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(R-115777. Oncolytic, farnesyl protein transferase inhibitor)

RN 192185-68-5 CA
CN 2(1H)-Quinolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 136:111918 CA
TITLE: Farnesyltransferase inhibitors
AUTHOR(S): Adjei, Alex A.
CORPORATE SOURCE: Division of Medical Oncology, Mayo Clinic, Rochester, MN, 55905, USA
SOURCE: Cancer Chemotherapy and Biological Response Modifiers (2001), 19, 149-164
CODEN: CCBAED; ISSN: 0921-4410
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review discusses the development, preclin. pharmacol., mechanism of action, clin. studies, and toxicity profile of farnesyltransferase inhibitors (FTIs). Farnesyltransferase inhibition was envisioned as a strategy for interfering with ras-dependent cell transformation, thus, various FTIs have been developed. Four FTIs are in clin. trials worldwide, with several more at different levels of preclin. development. Two of these, R115777 and SCH66336, are orally active heterocyclic compds. and are in phase II studies. The other two agents, L778123 and BMS214662, are administered i.v. and are in phase I trials.

IT **192185-68-5**, R115777
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyltransferase inhibitors)

RN 192185 68-5 CA
CN 2(1H)-Quinolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H imidazol-5-yl)methyl]-4 (3-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 112 THERE ARE 112 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 136:31714 CA
TITLE: Method for treating Alzheimer's disease
INVENTOR(S): Ahn, Kyunghye; Emmerling, Mark Richard; Haske, Taraneh; Hupe, Donald J.; Sebolt-Leopold, Judith; Levine, Harry; Scholten, Jeffrey David
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001051642	A1	20011213	US 2001-771529	20010129
<--				
US 2004063770	A1	20040401	US 2003-671385	20030926
PRIORITY APPLN. INFO.:			US 2000-197484P	P 20000417
			US 2001-771529	B1 20010129

GI



I

AB The present invention provides methods and compns. for inhibiting A.beta.(.beta.-amyloid peptide) synthesis and for treating Alzheimer's disease by administering a farnesyl transferase inhibitor of the formula I; wherein R is hydrogen, alkyl, and substituted alkyl; R1 is hydrogen, Ph, or substituted phenyl; and R2 is hydrogen or benzyl.

IT **192185-68-5**
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treating Alzheimer's disease by inhibiting .beta.-amyloid peptide synthesis using farnesyl transferase inhibitors such as dihydronaphthalenones)

RN 192185-68-5 CA
CN 2(1H)-Quinolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



L7 ANSWER 6 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 136:73 CA
TITLE: Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies
AUTHOR(S): Karp, Judith E.
CORPORATE SOURCE: Departments of Medicine and Oncology, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA
SOURCE: Seminars in Hematology (2001), 38(3, Suppl. 7), 16-23
CODEN: SEHEA3; ISSN: 0037-1963
PUBLISHER: W. B. Saunders Co.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Farnesyl protein transferase inhibitors (FTIs) represent a new class of anticancer agents specifically targeting aberrant biol. processes involved with cellular transformation and malignancy. Originally developed to inhibit tumors by preventing activation of oncogenic ras genes via suppression of their posttranslational farnesylation, their anticancer activity appears to stem from their ability to inhibit famesylation of various proteins that mediate signal transduction, growth, apoptosis, and angiogenesis. The safety, biol. activity, clin. response, and pharmacokinetics of R115777, a potent, orally active FTI, were recently investigated in a phase I dose-ranging study in patients with acute leukemias. Patients with acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), or chronic myelogenous leukemia (CML) in blast crisis received R115777 100 mg, 300 mg, 600 mg, 900 mg, or 1,200 mg twice daily for 21 days. Cycles were repeated every 28 to 31 days for up to four cycles. An overall response rate of 29% (10/34 evaluable patients) was obsd. across all R115777 doses. R115777 was well tolerated; common adverse events included fatigue, increased creatinine, nausea, and neutropenia. Dose limiting toxicity occurred at 1,200 mg twice daily. Farnesylation of lamin A and HDJ-2, examd. as biol. end points, was inhibited by R115777 doses .gtoreq. 600 mg twice daily. Pharmacokinetic evaluation suggests that R115777 is concd. in bone marrow at steady state. The biol. and antitumor activity and favorable tolerability of R115777 support further clin. evaluation alone and in combination therapy in hematol. malignancies.

IT **192185-68-5**, R115777
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl protein transferase inhibitors as targeted therapies for hematol. malignancies in humans)

RN 192185-68-5 CA
CN 2(1H)-Quinolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L7 ANSWER 7 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:376782 CA
TITLE: Drug combinations for prevention of restenosis
INVENTOR(S): Kopia, Gregory A.; Llanos, Gerald H.; Falotico, Robert F.
PATENT ASSIGNEE(S): Cordis Corporation, USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087372 <--	A1	20011122	WO 2001-US13780	20010425
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001062957 <--	A5	20011126	AU 2001-62957	20010425
EP 1289576	A1	20030312	EP 2001 937196	20010425
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003533493	T2	20031111	JP 2001 583836	20010425
PRIORITY APPLN. INFO.:			US 2000-204417P	P 20000512
			US 2000 575480P	P 20000519
			US 2000-575480	A 20000519
			WO 2001-US13780	W 20010425

AB The current invention comprises an approach to solving the clin. problem of restenosis, which involves the administration of combinations of drugs to patients undergoing PTCA or stent implantation. In one embodiment of the invention, an antiproliferative agent such as rapamycin, vincristine or taxol is administered in combination with the antiinflammatory agent, dexamethasone, to patients systemically, either s.c. or i.v. In another embodiment of the invention, the antiproliferative and antiinflammatory agents are bound in a single formulation to the surface of a stent by means of incorporation within either a biodegradable or biostable polymeric coating. Alternatively, such drug combinations could be incorporated into a stent constructed with a grooved reservoir. Stents were coated with Parylene-C by using a vapor deposition method. The stent was weighed and then mounted for coating. While the stent was rotating a soln. of 1.75 mg/mL poly(ethylene-co-vinyl acetate) (PEVA), 1.75 mg/mL poly(Bu methacrylate), 0.75 mg/mL rapamycin and 0.75 mg/mL dexamethasone dissolved in THF was sprayed onto it. The coated stent was removed from the spray and allowed to air-dry. After a final weighing the amt. of coating on the stent was detd.

L7 ANSWER 7 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)

IT **192185-68-5**, R 115777
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug combinations for prevention of restenosis)

RN 192185-68-5 CA
CN 2(1H)-Quinolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L7 ANSWER 8 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:298316 CA
TITLE: Phase I trial of oral R115777 in patients with refractory solid tumors: preliminary results
AUTHOR(S): Hudes, Gary R.; Schol, Jessie
CORPORATE SOURCE: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
SOURCE: Farnesyltransferase Inhibitors in Cancer Therapy (2001), 251-254. Editor(s): Sebti, Said M.; Hamilton, Andrew D. Humana Press Inc.: Totowa, N. J. CODEN: 69BMXX
DOCUMENT TYPE: Conference
LANGUAGE: English

AB Several protein farnesyltransferase (FTase) inhibitors (FTI) are completing evaluation in Phase I clin. trials. RI115777, an orally bioavailable substituted quinone, is among the first FTI to undergo evaluation in humans. This chapter summarizes the preliminary results of a Phase I trial of R115777 administered orally, twice daily (bid) for 21 consecutive days, conducted at Fox Chase Cancer Center. Because continuous administration would be preferable for an agent with cytostatic rather than cytotoxic properties, a 21-d treatment schedule was selected for the second US Phase I trial, with cycles repeated every 28 d. The starting dose of R115777 was 60 mg/ m2 or approx 100 mg twice daily, based on the tolerability of this dose and five fold higher doses in the earlier NCI Phase I trial. A Bayesian dose escalation design, Escalation with Overdose Control (EWOC), provided rules for dose escalation or de-escalation, depending upon the overall toxicity experience in all patients (4). A total of 22 patients were enrolled and treated at doses ranging from 100 to 800 mg bid. All patients registered participated in pharmacokinetic studies. Of the initial 22 patients enrolled, 14 were male and 8 were female, with median age of 59 yr (range 35-73 yr). The tumor types represented were colorectal (7 patients), pancreatic carcinoma (4 patients), nonsmall cell lung cancer (2 patients), and one patient each (n = 9) with a variety of other tumors including renal, prostate, salivary gland, and hepatocellular cancers. None of these patients experienced grade 3 or 4 neutropenia or thrombocytopenia, including two patients treated for 7 and 8 cycles, resp., without toxicity. Other toxic effects were mild and uncommon. Plasma R115777 concn. data for all 22 patients were analyzed using noncompartmental methods. The preliminary findings of this Phase I trial indicate that R115777 can be administered safely for 21 consecutive days at doses that produce plasma concns. capable of inhibiting FTase. The wide interpatient pharmacokinetic variability of R115777 is similar to that obsd. with other orally administered agents. Fatigue, nausea, and diarrhea were common, but usually mild. Rash, creatinine elevation, and hyperbilirubinemia were sporadic, reversible toxicities. Considering all the Phase I trials together, the clin. toxicity of R115777 in humans has mirrored the preclin. toxicity profile in dogs. Phase II studies employing the 21-d, bid schedule of R115777 in a variety of tumor types will commence in the year 2000.

L7 ANSWER 8 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)

IT **192185-68-5**, R115777
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(oral R115777 in humans with refractory solid tumors)
RN 192185-68-5 CA
CN 2(1H)-Quinolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:221275 CA
TITLE: Farnesyl protein transferase inhibitor combinations with an HER2 antibody
INVENTOR(S): Horak, Ivan David; Bowden, Christopher J.
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064246	A2	20010907	WO 2001-EP2163	20010226
WO 2001064246	A3	20020221		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1267929	A2	20030102	EP 2001-927707	20010226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525252	T2	20030826	JP 2001-563143	20010226
US 2003022918	A1	20030130	US 2002-220217	20020828
PRIORITY APPLN. INFO.:			EP 2000-200692 A	20000229
			WO 2001 EP2163 W	20010226

OTHER SOURCE(S): MARPAT 135:221275
GI



I

AB The present invention is concerned with combinations of a farnesyl transferase inhibitor and an HER2 antibody for inhibiting the growth of tumor cells and useful in the treatment of cancer. An example farnesyl transferase inhibitor is I.

L7 ANSWER 9 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)

IT **192185-51-6**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl protein transferase inhibitor antitumor combinations with an HER2 antibody)
RN 192185-51-6 CA
CN 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 10 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:221274 CA
TITLE: Farnesyl protein transferase inhibitor combinations as anticancer agents
INVENTOR(S): Rybak, Mary Ellen Margaret
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064218 <--	A2	20010907	WO 2001-EP2169	20010226
WO 2001064218	A3	20020321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1261342	A2	20021204	EP 2001-925358	20010226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525245	T2	20030826	JP 2001-563115	20010226
US 2003125326	A1	20030703	US 2002-220218	20020828
PRIORITY APPLN. INFO.:			EP 2000-200693 A	20000229
			WO 2001-EP2169 W	20010226

OTHER SOURCE(S): MARPAT 135:221274
AB The present invention is concerned with combinations of two or more farnesyl transferase inhibitors (Markush structures given) for inhibiting the growth of tumor cells and useful in the treatment of cancer (no data).
IT **192185-51-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(farnesyl protein transferase inhibitor combinations as anticancer agents)
RN 192185-51-6 CA
CN 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl] 1 methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 10 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



L7 ANSWER 11 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:221273 CA
TITLE: Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
INVENTOR(S): Rybak, Mary Ellen Margaret
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064217 <--	A2	20010907	WO 2001-EP2168	20010226
WO 2001064217	A3	20020328		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1261348	A2	20021204	EP 2001-907564	20010226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525244	T2	20030826	JP 2001-563114	20010226
US 2003078281	A1	20030424	US 2002-220220	20020828
PRIORITY APPLN. INFO.:			EP 2000-200691 A	20000229
			WO 2001-EP2168 W	20010226

OTHER SOURCE(S): MARPAT 135:221273
AB The present invention is concerned with combinations of a farnesyl transferase inhibitor and an anti-tumor alkylating agent (Markush structures given) for inhibiting the growth of tumor cells and useful in the treatment of cancer (no data).
IT **192185-51-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents)
RN 192185-51-6 CA
CN 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl (9CI) (CA INDEX NAME)

L7 ANSWER 11 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



L7 ANSWER 12 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:221271 CA
TITLE: Farnesyl protein transferase inhibitor combinations with antitumor podophyllotoxin derivatives
INVENTOR(S): Rybak, Mary Ellen Margaret
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064198 <--	A2	20010907	WO 2001-EP2167	20010226
WO 2001064198	A3	20020321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1267871	A2	20030102	EP 2001-913838	20010226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525238	T2	20030826	JP 2001-563095	20010226
US 2003050323	A1	20030313	US 2002-220216	20020828
PRIORITY APPLN. INFO.:			EP 2000-200695 A	20000229
			WO 2001-EP2167 W	20010226

OTHER SOURCE(S): MARPAT 135:221271
GI



I

L7 ANSWER 12 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)
AB The present invention is concerned with combinations of a farnesyl transferase inhibitor and an antitumor podophyllotoxin deriv. for inhibiting the growth of tumor cells and useful in the treatment of cancer. An example farnesyl transferase inhibitor is I and podophyllotoxin deriv. is etoposide.
IT **192185-51-6**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl protein transferase inhibitor combinations with antitumor podophyllotoxin derivs.)
RN 192185-51-6 CA
CN 2(1H)-Quinolinone,
4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 13 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:221270 CA
TITLE: Farnesyl protein transferase inhibitor combinations with Vinca alkaloids
INVENTOR(S): Horak, Ivan David; Bowden, Christopher J.
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064196 <--	A2	20010907	WO 2001-EP2165	20010226
WO 2001064196	A3	20020321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1263437	A2	20021211	EP 2001-915297	20010226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525236	T2	20030826	JP 2001-563093	20010226
US 2003060480	A1	20030327	US 2002-220398	20020828
PRIORITY APPLN. INFO.:			EP 2000-200698 A	20000229
			WO 2001-EP2165 W	20010226

OTHER SOURCE(S): MARPAT 135:221270
GI



I

AB The present invention is concerned with combinations of a farnesyl transferase inhibitor and a Vinca alkaloid for inhibiting the growth of tumor cells and useful in the treatment of cancer. An example farnesyl transferase inhibitor is I and alkaloid is vinblastine.

L7 ANSWER 13 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)
IT **192185-51-6**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl protein transferase inhibitor combinations with Vinca alkaloids)
RN 192185-51-6 CA
CN 2(1H)-Quinolinone,
4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 14 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:221269 CA
TITLE: Farnesyl protein transferase inhibitor combinations with antitumor nucleoside derivatives
INVENTOR(S): Palmer, Peter Albert; Horak, Ivan David
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064195 <--	A2	20010907	WO 2001-EP2164	20010226
WO 2001064195	A3	20020321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1261343	A2	20021204	EP 2001-929363	20010226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525235	T2	20030826	JP 2001-563092	20010226
US 2003186925	A1	20031002	US 2002 220395	20020828
PRIORITY APPLN. INFO.:			EP 2000-200697 A	20000229
			WO 2001 EP2164 W	20010226

OTHER SOURCE(S): MARPAT 135:221269
GI



I

L7 ANSWER 14 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)
AB The present invention is concerned with combinations of a farnesyl transferase inhibitor and an antitumor nucleoside deriv. for inhibiting the growth of tumor cells and useful in the treatment of cancer. An example farnesyl transferase inhibitor is I and nucleoside deriv. is 5-fluorouracil.
IT **192185-51-6**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl protein transferase inhibitor combinations with antitumor nucleoside derivs.)
RN 192185-51-6 CA
CN 2(1H)-Quinolinone,
4-(3 chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol 5-yl)methyl] 1-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 15 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:221268 CA
TITLE: Farnesyl protein transferase inhibitor combinations with camptothecin compounds
INVENTOR(S): Palmer, Peter Albert; Horak, Ivan David
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064194 <--	A2	20010907	WO 2001-EP2161	20010226
WO 2001064194	A3	20020307		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1261341	A2	20021204	EP 2001 911702	20010226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525234	T2	20030826	JP 2001-563091	20010226
US 2003100553	A1	20030529	US 2002-220399	20020828
PRIORITY APPLN. INFO.:			EP 2000-200688 A	20000229
			WO 2001-EP2161 W	20010226

OTHER SOURCE(S): MARPAT 135:221268
GI



I

AB The present invention is concerned with combinations of a farnesyl transferase inhibitor and a camptothecin compd. for inhibiting the growth of tumor cells and useful in the treatment of cancer. An example farnesyl

L7 ANSWER 15 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)
transferase inhibitor is I and example camptothecin compd. is topotecan.
IT **192185-51-6**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl protein transferase inhibitor combinations with camptothecin compds.)
RN 192185-51-6 CA
CN 2(1H)-Quinolinone,
4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 16 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:216007 CA
TITLE: Farnesyl protein transferase inhibitor combinations of (imidazol-5-yl)methyl-2-quinolinones with anticancer agents
INVENTOR(S): Palmer, Peter Albert; Horak, Ivan David
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064252 <--	A2	20010907	WO 2001-EP2162	20010226
WO 2001064252	A3	20020321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1261374	A2	20021204	EP 2001-917032	20010226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525255	T2	20030826	JP 2001-563149	20010226
US 2003212008	A1	20031113	US 2002-220219	20020828
PRIORITY APPLN. INFO.:			EP 2000-200694 A	20000229
			WO 2001-EP2162 W	20010226

OTHER SOURCE(S): MARPAT 135:216007
AB The present invention is concerned with combinations of a farnesyl transferase inhibitor, e.g., (imidazol-5-yl)methyl-2-quinolinones, and 2 or more anticancer agents for inhibiting the growth of tumor cells and useful in the treatment of cancer. The anticancer agents can be selected from, e.g., taxanes, vinca alkaloids, podophyllotoxins.
IT **192185-51-6**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl protein transferase inhibitor combinations of (imidazolyl)methylquinolinones with anticancer agents)
RN 192185-51-6 CA
CN 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 16 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



L7 ANSWER 17 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:216005 CA
TITLE: Farnesyl protein transferase inhibitor combinations with platinum compounds as anticancer agents
INVENTOR(S): Palmer, Peter Albert; Horak, Ivan David
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064226 <--	A2	20010907	WO 2001-EP2160	20010226
WO 2001064226	A3	20020307		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1261356	A2	20021204	EP 2001-919347	20010226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525246	T2	20030826	JP 2001-563123	20010226
US 2003027808	A1	20030206	US 2002-220397	20020828
PRIORITY APPLN. INFO.:			EP 2000-200690 A	20000229
			WO 2001-EP2160 W	20010226

OTHER SOURCE(S): MARPAT 135:216005
AB The present invention is concerned with combinations of a farnesyl transferase inhibitor, e.g., (imidazol-5-yl)methyl-2-quinolinones, and a platinum compd. for inhibiting the growth of tumor cells and useful in the treatment of cancer.
IT **192185-51-6**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl protein transferase inhibitor combinations with platinum compds. as anticancer agents)
RN 192185-51-6 CA
CN 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 17 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



L7 ANSWER 18 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:216000 CA
TITLE: Farnesyl protein transferase inhibitor combinations of (imidazol-5-yl)methyl-2-quinolinones with taxanes as anticancer agents
INVENTOR(S): Palmer, Peter Albert; Horak, Ivan David
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064199	A2	20010907	WO 2001-EP2170	20010226
<--				
WO 2001064199	A3	20011227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1265611	A2	20021218	EP 2001-919348	20010226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525239	T2	20030826	JP 2001-563096	20010226
US 2003181473	A1	20030925	US 2002-220396	20020828
PRIORITY APPLN. INFO.:			EP 2000-200689 A	20000229
			WO 2001-EP2170 W	20010226

OTHER SOURCE(S): MARPAT 135:216000
AB The present invention is concerned with combinations of a farnesyl transferase inhibitor, e.g., (imidazol-5-yl)methyl-2 quinolinones, and a taxane for inhibiting the growth of tumor cells and useful in the treatment of cancer. The farnesyl transferase inhibitor is advantageously administered at 0.0001-100 mg/kg and the taxane at 50-400 mg.
IT **192185-51-6**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl protein transferase inhibitor combinations of (imidazolyl)methylquinolinones with taxanes as anticancer agents)
RN 192185-51-6 CA
CN 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 18 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



L7 ANSWER 19 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:215999 CA
TITLE: Farnesyl protein transferase inhibitor combinations with antitumor anthracycline derivatives
INVENTOR(S): Rybak, Mary Ellen Margaret
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064197	A2	20010907	WO 2001-EP2166	20010226
<--				
WO 2001064197	A3	20020321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1267872	A2	20030102	EP 2001-917033	20010226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525237	T2	20030826	JP 2001-563094	20010226
US 2003125268	A1	20030703	US 2002-220222	20020828
PRIORITY APPLN. INFO.:			EP 2000-200696 A	20000229
			WO 2001-EP2166 W	20010226

OTHER SOURCE(S): MARPAT 135:215999
AB The present invention is concerned with combinations of a farnesyl transferase inhibitor, (imidazol-5-yl)methyl-2-quinolinones, and an anthracycline deriv. for inhibiting the growth of tumor cells and useful in the treatment of cancer. The farnesyl transferase inhibitor is advantageously administered at 0.0001-100 mg/kg and the taxane at 10-75 mg.
IT **192185-51-6**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl protein transferase inhibitor combinations with antitumor anthracycline derivs.)
RN 192185-51-6 CA
CN 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 19 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



L7 ANSWER 20 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:207523 CA
TITLE: Magnetic resonance detects changes in phosphocholine associated with ras activation and inhibition in NIH 3T3 cells
AUTHOR(S): Ronen, S. M.; Jackson, L. E.; Beloueche, M.; Leach, M.
O.
CORPORATE SOURCE: Cancer Research Campaign (CRC) Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Royal Marsden Hospital, Sutton, SM2 5PT, UK
SOURCE: British Journal of Cancer (2001), 84(5), 691-696
CODEN: BJCAAI; ISSN: 0007-0920
PUBLISHER: Harcourt Publishers Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Ras is frequently mutated in cancer, and novel therapies are being developed to target Ras signalling. To identify non-invasive surrogate markers of Ras activation and inhibition, the authors used 31P magnetic resonance spectroscopy (MRS) and investigated NIH 3T3 cells compared to a mutant ras transfected counterpart. The MR spectra indicated that phosphocholine (PC) levels increased significantly from 3 .+-. 2 fmol cell 1 in NIH 3T3 cells to 13 .+-. 4 fmol cell-1 in the transfected cells.
The PC/NTP ratio increased significantly from 0.3 .+-. 0.1 to 0.7 .+-. 0.3. This could not be explained by either a faster proliferation rate or
by alterations in cell cycle distribution. Both cell lines were treated with simvastatin, 17 AAG and R115777, agents which inhibit Ras signalling.
Cell proliferation was inhibited in both cell lines. The spectrum of NIH 3T3 cells was not affected by treatment. In contrast, in the ras transfected cells growth inhibition was assocd. with an av. 35 .+-. 5% drop in PC levels and a comparable drop in PC/NTP. Thus the MRS visible increase in phosphocholine is assocd. with Ras activation, and response to
treatment is assocd. with partial reversal of phosphocholine increase in ras transfected cells. MRS might therefore be a useful tool in detecting Ras activation and its inhibition following targeted therapies.

IT **192185-68-5**, R115777
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(antitumor effect on phosphocholine assocd. with ras activation and inhibition in NIH 3T3 cells detected by 31P-NMR)

RN 192185-68-5 CA
CN 2(1H)-Quinolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 20 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L7 ANSWER 21 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:205526 CA
TITLE: Treatment of mammalian tumors with farnesyl protein transferase inhibitors and dosing regimen
INVENTOR(S): End, David William
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062234 <--	A2	20010830	WO 2001-EP1937	20010220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1267848	A1	20030102	EP 2001-903785	20010220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003523381	T2	20030805	JP 2001-561301	20010220
US 2003060450	A1	20030327	US 2002-220162	20020823
PRIORITY APPLN. INFO.:			US 2000 184551P	P 20000224
			WO 2001-EP1937	W 20010220

OTHER SOURCE(S): MARPAT 135:205526

AB The present invention relates to a method of treating mammalian tumors which comprises administering a single dose of a farnesyl protein transferase (FPT) inhibitor over a one to five day period. The invention also relates to an antitumor dosage regimen in which suppression of tumor growth is achieved by the administration of an FPT inhibitor over a one to
five day period followed by at least two weeks without treatment. The transient one to five day exposure of mammalian tumors to an FPT inhibitor
produces sustained antitumor effects. The inhibition of FPT by a FPT inhibitor under the method and regimen of the present invention produces lasting alterations in the malignant process which recover only very slowly.

IT **192185-51-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(treatment of mammalian tumors with farnesyl protein transferase inhibitors and dosing regimen)

RN 192185-51-6 CA
CN 2(1H) Quinolinone,
4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-

L7 ANSWER 21 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)
1H-imidazol-5-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 22 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:162212 CA
TITLE: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
AUTHOR(S): Karp, Judith E.; Lancet, Jeffrey E.; Kaufmann, Scott H.; End, David W.; Wright, John J.; Bol, Kees; Horak, Ivan; Tidwell, Michael L.; Liesveld, Jane; Kottke, Timothy J.; Ange, Dawn; Buddharaju, Laxmi; Gojo, Ivana; Highsmith, W. Edward; Belly, Robert T.; Hohl, Raymond J.; Rybak, Mary Ellen; Thibault, Alain; Rosenblatt, Joseph
CORPORATE SOURCE: University of Maryland Greenebaum Cancer Center, Baltimore, MD, 21201, USA
SOURCE: Blood (2001), 97(11), 3361-3369
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: American Society of Hematology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB R115777 is a non-peptidomimetic enzyme-specific inhibitor of farnesyl protein transferase (FT) that was developed as a potential inhibitor of Ras protein signaling, with antitumor activity in preclin. models. This study was a phase 1 trial of orally administered R115777 in 35 adults with poor-risk acute leukemias. Cohorts of patients received R115777 at doses ranging from 100 mg twice daily (bid) to 1200 mg bid for up to 21 days. Dose-limiting toxicity occurred at 1200 mg bid, with central neurotoxicity evidenced by ataxia, confusion, and dysarthria. Non-dose-limiting toxicities included reversible nausea, renal insufficiency, polydipsia, paresthesias, and myelosuppression. R115777 inhibited FT activity at 300 mg bid and farnesylation of FT substrates lamin A and HDJ-2 at 600 mg bid. Extracellular signal-regulated kinase (ERK), an effector enzyme of Ras-mediated signaling, was detected in its phosphorylated (activated) form in 8 (36.4%) of 22 pretreatment marrows and became undetectable in 4 of those 8 after one cycle of treatment. Pharmacokinetics revealed a linear relationship between dose and max. plasma concn. or area under the curve over 12 h at all dose levels. Weekly marrow samples demonstrated that R115777 accumulated in bone marrow in a dose-dependent fashion, with large increases in marrow drug levels beginning at 600 mg bid and with sustained levels throughout drug administration. Clin. responses occurred in 10 (29%) of the 34 evaluable patients, including 2 complete remissions. Genomic analyses failed to detect N-ras gene mutations in any of the 35 leukemias. The results of this first clin. trial of a signal transduction inhibitor in patients with acute leukemias suggest that inhibitors of FT may have important clin. antileukemic activity.
IT **192185-68-5**, R115777
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC

L7 ANSWER 22 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)
(Process); USES (Uses)
(clin. and biol. activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias)
RN 192185-68-5 CA
CN 2(1H)-Quinolinone, 6 [amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3 chlorophenyl)-1 methyl (9CI) (CA INDEX NAME)



REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L7 ANSWER 23 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:147414 CA
TITLE: Farnesyl protein transferase inhibitors for treating breast cancer
INVENTOR(S): Palmer, Peter Albert; Horak, Ivan David
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056552	A2	20010809	WO 2001-EP1032	20010201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1255537	A2	20021113	EP 2001-905717	20010201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003521509	T2	20030715	JP 2001-556244	20010201
US 2003027839	A1	20030206	US 2002-203083	20020802

PRIORITY APPLN. INFO.: EP 2000-200373 A 20000204
WO 2001-EP1032 W 20010201

OTHER SOURCE(S): MARPAT 135:147414
AB The invention relates to the use of farnesyl protein transferase inhibitors for prepg. pharmaceutical compns. for treating advanced breast cancer.
IT **192185-51-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl protein transferase inhibitors for treating breast cancer)
RN 192185-51-6 CA
CN 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



L7 ANSWER 24 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:137507 CA
TITLE: Anticancer compound (+)-6-[amino(6-chloropyridin-3-yl)(3-methyl-3H-imidazol 4-yl)methyl]-4 (3-chlorophenyl)-1-cyclopropylmethyl-1H-quinolin-2-one and enantiomer separation method useful for its synthesis
INVENTOR(S): Yang, Bingwei Vera
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053289	A1	20010726	WO 2000-IB1769	20001129

<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BR 2000016986	A	20021008	BR 2000-16986	20001129
EP 1248782	A1	20021016	EP 2000-976213	20001129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003520796	T2	20030708	JP 2001-553763	20001129
US 2002004514	A1	20020110	US 2001-761994	20010117
US 6479513	B2	20021112		
PRIORITY APPLN. INFO.:			US 2000-177718P	P 20000121
			WO 2000-IB1769	W 20001129

OTHER SOURCE(S): MARPAT 135:137507
GI

L7 ANSWER 24 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



I

AB The invention relates to the compd. (+)-6-[amino(6 chloropyridin-3 yl)(3-methyl-3H-imidazol 4-yl)methyl]-4 (3-chlorophenyl)-1-cyclopropylmethyl-1H-quinolin-2-one [(+)-I], pharmaceutically acceptable salts and solvates thereof, prodrugs thereof, and to the use of (+)-I for inhibiting abnormal cell growth, including cancer, in mammals. The invention also relates to methods useful in synthesizing (+)-I. These include resoln. of (.+-.)-I by chiral sepn., or alternatively resoln. of racemic N-(substituted)benzyl or N-(substituted)benzylidene derivs. of I using chiral sepn., followed by deprotection of the (+)-I derivs. (+)-I is a more potent inhibitor of farnesyl protein transferase (FTase) than ( )-I. For instance, the N-(4-methoxybenzylidene) deriv. of I was prepd. in 3 steps and resolved by HPLC on CHIRALCEL.RTM. OD with >99% optical purity for both (+)- and (-)-isomers. Cleavage of the (-)-isomer with aq. HCl in THF gave (+)-I in 90% yield and >99% optical purity. (+)-I inhibited farnesylation of biotinylated KTKCVIS-peptide by human FTase in vitro with an IC50 value of less than 500 nM.

IT **288391-56-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. and resoln. of [amino(chloropyridinyl)(methylimidazolyl)methyl](chlorophenyl)(cyclopropylmethyl)quinolinone enantiomer as anticancer agent)

RN 288391-56-0 CA
CN 2(1H)-Quinolinone, 6-[amino(6-chloro-3 pyridinyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 24 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L7 ANSWER 25 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 135:70616 CA
TITLE: Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors
AUTHOR(S): Punt, C. J. A.; Van Maanen, L.; Bol, C. J. J. G.; Seifert, W. F.; Wagener, D. J. Th
CORPORATE SOURCE: Department of Medical Oncology, University Medical Center St Radboud, Nijmegen, 6500 HB, Neth.
SOURCE: Anti-Cancer Drugs (2001), 12(3), 193-197
CODEN: ANTDEV; ISSN: 0959-4973
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English

AB R115777 is a novel selective inhibitor of farnesyl transferase, an enzyme that is involved in the proliferation of the malignant cell type. This study was designed to det. the toxicity, maximal tolerated dose and pharmacokinetics of R115777 when given orally b.i.d. for 28 days followed by 1-2 wk of rest. Patients with advanced solid tumors for whom no std. therapy was available could enter the study. The starting dose of R115777 was 200 mg/dose and inter- as well as intra-patient dose escalations were performed with increments of 100 mg/dose. Nine patients entered the study and received in total 23 treatment cycles. A dose of 300 mg b.i.d. proved feasible with grade 4 neutropenia occurring in one of six patients who completed the first treatment cycle. Other toxicities were infrequent. Pharmacokinetic anal. demonstrated that peak plasma concns. of 881 .+-. 393 ng/mL were reached within 1-5 h. No accumulation of R115777 was obsd. over a 28 day period. The study was terminated based on these results together with the observation from a related phase I study in which higher doses of R115777 were assocd. with the frequent occurrence of grade 3-4 myelosuppression. We conclude that the recommended dose of R115777 given for 28 days followed by 1 2 wk of rest is 300 mg b.i.d. Myelosuppression is the dose-limiting toxicity.

IT **192185-68-5**, R115777
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmacokinetics of the farnesyl transferase inhibitor R115777 in patients with advanced solid tumors)

RN 192185-68-5 CA
CN 2(1H)-Quinolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 25 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 26 OF 40 CA COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 134:361346 CA

TITLE: Product inhibiting heterotrimeric G protein signal transduction combined with another anticancer agent for therapeutic use in cancer treatment

INVENTOR(S): Prevost, Gregoire; Lonchampt, Marie-Odile; Gordon, Thomas; Morgan, Barry

PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.), Fr.

SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001034203	A1	20010517	WO 2000-FR3098	20001108

<--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

FR 2800616	A1	20010511	FR 1999-14037	19991109

< -

FR 2800616	B1	20020118		
FR 2803524	A1	20010713	FR 2000-104	20000106

<--

FR 2803524	B1	20020419		
EP 1233787	A1	20020828	EP 2000-976116	20001108

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

EP 1430934	A1	20040623	EP 2004-75491	20001108

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR

PRIORITY APPLN. INFO.:

FR 1999-14037	A	19991109
FR 2000-104	A	20000106
EP 2000-976116	A3	20001108
WO 2000-FR3098	W	20001108

OTHER SOURCE(S): MARPAT 134:361346

AB The invention provides a product inhibiting heterotrimeric G protein signal transduction combined with another anticancer agent, in particular a farnesyltransferase inhibitor, taxol or gemcitabine, for simultaneous, sep., or prolonged therapeutic use in cancer treatment.

IT **192185-68-5**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L7 ANSWER 26 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)

study, unclassified); THU (Therapeutic use); BIOL (Biological study);

USES

(Uses)

(heterotrimeric G protein signal transduction inhibitor combined with another anticancer agent for cancer treatment)

RN 192185-68-5 CA

CN 2(1H)-Quinolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 27 OF 40 CA COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 134:260999 CA

TITLE: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro

AUTHOR(S): End, David W.; Smets, Gerda; Todd, Alison V.; Applegate, Tanya L.; Fuery, Caroline J.; Angibaud, Patrick; Venet, Marc; Sanz, Gerard; Poignet, Herve; Skrzat, Stacy; Devine, Ann; Wouters, Walter; Bowden, Charles

CORPORATE SOURCE: Department of Oncology, Janssen Research Foundation, Spring House, PA, 19477, USA

SOURCE: Cancer Research (2001), 61(1), 131-137
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB R115777 {(B)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone} is a potent and selective inhibitor of farnesyl protein transferase with significant antitumor effects in vivo subsequent to oral administration in mice. In vitro, using isolated human farnesyl protein transferase, R115777 competitively inhibited the farnesylation of lamin B and K-RasB peptide substrates, with IC50s of 0.86 nM and 7.9 nM, resp. In a panel of 53 human tumor cell lines tested for growth inhibition, .apprx.75% were sensitive to R115777. The majority of sensitive cell lines had a wild type ras gene. Tumor cell lines bearing H-ras or N-ras mutations were among the most sensitive of the cell lines tested, with responses obsd. at nanomolar concns. of R115777. Tumor cell lines bearing mutant K-ras genes required higher concns. for inhibition of cell growth, with 50% of the cell lines resistant to R115777 up to concns. of 500 nM. Inhibition of H-Ras, N-Ras, and lamin B protein processing was obsd. at concns. of R115777 that inhibited cell proliferation. However, inhibition of K-RasB protein-processing could not be detected. Oral administration b.i.d. of R115777 to nude mice bearing s.c. tumors at doses ranging from 6.25-100 mg/kg inhibited the growth of tumors bearing mutant H-ras, mutant K-ras, and wild type ras genes. Histol. evaluations revealed heterogeneity in tumor responses to R115777. In LoVo human colon tumors, treatment with R115777 produced a prominent antiangiogenic response. In CAPAN 2 human pancreatic tumors, an antiproliferative response predominated, whereas in C32 human melanoma, marked induction of apoptosis was obsd. The heterogeneity of histol. changes assocd. with antitumor effects suggested that R115777, and possibly farnesyl protein transferase inhibitors as a class, alter processes of transformation related to tumor-host interactions in addn. to inhibiting tumor-cell proliferation.

IT **192185-68-5**, R115777

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(antitumor effects of selective farnesyl protein transferase inhibitor R115777)

RN 192185-68-5 CA

CN 2(1H)-Quinolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 27 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L7 ANSWER 28 OF 40 CA COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 133:177111 CA
TITLE: Preparation of heteroaryl-substituted quinolin-2-ones as anticancer agents
INVENTOR(S): Yang, Bingwei Vera
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047574	A1	20000817	WO 2000-IB121	20000204
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1150973	A1	20011107	EP 2000 901292	20000204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200102315	T2	20011221	TR 2001-200102315	20000204
BR 2000008202	A	20020219	BR 2000-8202	20000204
TR 200201297	T2	20020621	TR 2002-200201297	20000204
TR 200201296	T2	20020722	TR 2002-200201296	20000204
JP 2002536444	T2	20021029	JP 2000-598494	20000204
EE 200100425	A	20021216	EE 2001-425	20000204
US 6258824	B1	20010710	US 2000-501163	20000209
US 2002019530	A1	20020214	US 2001-836026	20010417
US 6388092	B2	20020514		
HR 2001000574	A1	20021231	HR 2001-574	20010730
ZA 2001006520	A	20020826	ZA 2001-6520	20010808
NO 2001003909	A	20011008	NO 2001-3909	20010810
BG 105860	A	20020329	BG 2001-105860	20010830
US 2002120145	A1	20020829	US 2002 92744	20020307
US 6710209	B2	20040323		
JP 2004182741	A2	20040702	JP 2004-29709	20040205

PRIORITY APPLN. INFO.:

US 1999 119702P	P	19990211
JP 2000-598494	A3	20000204
WO 2000-IB121	W	20000204
US 2000-501163	A3	20000209

L7 ANSWER 28 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)
US 2001-836026 A3 20010417

OTHER SOURCE(S): MARPAT 133:177111
GI



AB The title compds. [I; R1 = H, alkyl, etc.; R2 = halo, CN, CO2H, etc.; R3 R7 = H, alkyl, alkenyl, etc.; Z = (un)substituted arom. 4-10 membered heterocyclyl; R8 = H, OH, CN, etc.; R9 = (un)substituted methyl(imidazolyl), methyl(pyridinyl)], useful for inhibiting abnormal cell growth, including cancer, were prepd. E.g., a multi-step synthesis of quinolin-2 one II, was given. Exemplified compds. I showed IC50 of .ltoreq. 500 nM against human farnesyl transferase in vitro.

IT **288391-15-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of heteroaryl-substituted quinolin-2-ones as anticancer agents)

RN 288391-15-1 CA
CN 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(6-chloro-3 pyridinyl)hydroxy(1-methyl 1H-imidazol-5-yl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L7 ANSWER 29 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 133:37688 CA
TITLE: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
AUTHOR(S): Zujewski, J.; Horak, I. D.; Bol, C. J.; Woestenborghs, R.; Bowden, C.; End, D. W.; Piotrovsky, V. K.; Chiao, J.; Belly, R. T.; Todd, A.; Kopp, W. C.; Kohler, D. R.; Chow, C.; Noone, M.; Hakim, F. T.; Larkin, G.; Gress, R. E.; Nussenblatt, R. B.; Kremer, A. B.; Cowan, K. H.
CORPORATE SOURCE: Medicine Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, 9000, USA
SOURCE: Journal of Clinical Oncology (2000), 18(4), 927 941
CODEN: JCONDN; ISSN: 0732-183X
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Purpose: To det. the max. tolerated dose, toxicities, and pharmacokinetic profile of the farnesyl protein transferase inhibitor R115777 when administered orally bid for 5 days every 2 wk. Patients and Methods: Twenty-seven patients with a median age of 58 yr received 85 cycles of R115777 using an intrapatient and interpatient dose escalation schema. Drug was administered orally at escalating doses as a soln. (25 to 850 mg bid) or as pellet capsules (500 to 1300 mg bid). Pharmacokinetics were assessed after the first dose and the last dose administered during cycle 1. Results: Dose limiting toxicity of grade 3 neuropathy was obsd. in one patient and grade 2 fatigue (decrease in two performance status levels) was seen in four of six patients treated with 1,300 mg bid. The most frequent clin. grade 2 or 3 adverse events in any cycle included nausea, vomiting, headache, fatigue, anemia, and hypotension. Myelosuppression was mild and infrequent. Peak plasma concns. of R115777 were achieved within 0.5 to 4 h after oral drug administration. The elimination of R115777 from plasma was biphasic, with sequential half lives of about 5 h and 16 h. There was little drug accumulation after bid dosing, and steady-state concns. were achieved within 2 to 3 days. The pharmacokinetics were dose proportional in the 25 to 325 mg/dose range for the oral soln. Urinary excretion of unchanged R115777 was less than 0.1% of the oral dose. One patient with metastatic colon cancer treated at the 500-mg bid dose had a 46% decrease in carcinoembryonic antigen levels, improvement in cough, and radiog. stable disease for 5 mo. Conclusion: R115777 is bioavailable after oral administration and has an acceptable toxicity profile. Based upon pharmacokinetic data, the recommended dose for phase II trials is 500 mg orally bid (total daily dose, 1,000 mg) for 5 consecutive days followed by 9 days of rest. Studies of continuous dosing and studies of R115777 in combination with chemotherapy are ongoing.

IT **192185-68-5**, R 115777
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC

L7 ANSWER 29 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)
(Process); USES (Uses)
(phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in humans with advanced cancer)
RN 192185-68-5 CA
CN 2(1H)-Quinolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L7 ANSWER 30 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 132:343356 CA
TITLE: A prenyl-protein transferase inhibitor for treating endometriosis
INVENTOR(S): Oliff, Allen I.; Gibbs, Jackson B.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 365 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000025789	A1	20000511	WO 1999-US25001	19991025

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1998-106179P P 19981029
GB 1999-160 A 19990105

OTHER SOURCE(S): MARPAT 132:343356

AB A method of preventing and treating endometriosis, uterine fibroids, dysfunctional uterine bleeding and endometrial hyperplasia is disclosed which is comprised of administering to a mammalian patient in need of such treatment an effective amt. of a prenyl-protein transferase inhibitor. Various in vitro inhibition assays for farnesyltransferase were developed and effect of a prenyl-protein transferase inhibitor (5-160 mg/kg/day) was evaluated in vitro in the rat model of endometriosis.

IT **192185-71-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protein prenyltransferase inhibitors for treatment of endometriosis and related disorders)
RN 192185-71-0 CA
CN 2(1H)-Quinolinone, 6-[(S)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L7 ANSWER 30 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L7 ANSWER 31 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 132:260674 CA
TITLE: A method of treating cancer using an HMG-CoA reductase inhibitor and a farnesyl-protein transferase inhibitor
INVENTOR(S): Graham, Samuel L.; Heimbrook, David C.; Koblan, Kenneth S.; Oliff, Allen I.; Stirdivant, Steven M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 342 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000016778 <--	A1	20000330	WO 1999-US21773	19990923
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9962564 <--	A1	20000410	AU 1999-62564	19990923
PRIORITY APPLN. INFO.:			US 1998 101633P	P 19980924
			GB 1998-24554	A 19981109
			WO 1999-US21773	W 19990923

AB The invention provides a method of treating cancer which comprises administering to a mammal a compn. which comprises an HMG-CoA reductase inhibitor and a farnesyl-protein transferase (FPT) inhibitor. Prepn. of FPT inhibitors is described.
IT **192185-68-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(HMG-CoA reductase inhibitor and farnesyl-protein transferase inhibitor for cancer treatment)
RN 192185-68-5 CA
CN 2(1H)-Quinolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L7 ANSWER 32 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 132:260673 CA
TITLE: A method of treating cancer using inhibitors of HMG-CoA reductase and prenyl-protein transferase
INVENTOR(S): Graham, Samuel L.; Koblan, Kenneth S.; Heimbrook, David C.; Oliff, Allen I.; Stirdivant, Steven M.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 196 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000016626 <--	A1	20000330	WO 1999-US22224	19990923
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9961624 <--	A1	20000410	AU 1999-61624	19990923
PRIORITY APPLN. INFO.:			US 1998 101623P	P 19980924
			GB 1998-24575	A 19981109
			WO 1999-US22224	W 19990923

AB A method of treating cancer comprises administering to a mammal a compn. contg. a first compd. which is an HMG-CoA reductase inhibitor and a second compd. which is a prenyl-protein transferase inhibitor, and which is efficacious in vivo as an inhibitor of the growth of cancer cells characterized by a mutated K4B-Ras protein. For example, 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)imidazolylmethyl]-2-piperazinone dihydrochloride was prepd. (among other compds.) and tested for the inhibitory activity against human farnesyl protein transferase; it was found to have IC50 of .ltoreq. 1 .mu.M.
IT **192185-72-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(compns. contg. inhibitors of HMG-CoA reductase and prenyl protein transferases for cancer treatment)
RN 192185-72-1 CA
CN 2(1H)-Quinolinone, 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L7 ANSWER 32 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L7 ANSWER 33 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 132:194300 CA
TITLE: Preparation of alkynyl-substituted quinolin 2 ones as anticancer agents
INVENTOR(S): La Greca, Susan Deborah; Lyssikatos, Joseph Peter
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012499	A1	20000309	WO 1999-IB1398	19990806

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2341690	AA	20000309	CA 1999-2341690	19990806
AU 9949254	A1	20000321	AU 1999-49254	19990806
BR 9913138	A	20010508	BR 1999-13138	19990806
EP 1107963	A1	20010620	EP 1999-933084	19990806

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

TR 200101343	T2	20010921	TR 2001 200101343	19990806
EE 200100118	A	20020617	EE 2001-118	19990806
JP 2002523504	T2	20020730	JP 2000-567527	19990806
JP 3495706	B2	20040209		
NZ 509372	A	20030829	NZ 1999-509372	19990806
US 6150377	A	20001121	US 1999-383755	19990826
US 6294552	B1	20010925	US 2000-628039	20000727
ZA 2001001173	A	20020412	ZA 2001-1173	20010212
NO 2001000964	A	20010426	NO 2001-964	20010226
HR 2001000142	A1	20020228	HR 2001-142	20010227
BG 105365	A	20011130	BG 2001-105365	20010320
US 2002128287	A1	20020912	US 2001-900401	20010706
US 6579887	B2	20030617		
PRIORITY APPLN. INFO.:			US 1998-98145P P	19980827

L7 ANSWER 33 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)

		WO 1999-IB1398 W	19990806
		US 1999-383755 A3	19990826
		US 2000 628039 A3	20000727

OTHER SOURCE(S): MARPAT 132:194300
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = H, alkyl, etc.; R2 = halo, CN, etc.; R3-R7 = H, alkyl, alkenyl, etc.; R8 = H, CN, OR12, etc.; R9 = (CR13R14)t(imidazolyl) (wherein t = 0 5 and said imidazolyl is optionally substituted by 1-2 R6 substituents); R10, R11 = R6; R12 = H, alkyl, etc.; R13, R14 = H, alkyl], useful in the treatment of hyperproliferative disorders (no data), such as cancer, were prepd. E.g., a multi-step synthesis of II was given. Compds. I are effective at 0.01 10 mg/kg/day.

IT **260050-74-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of alkynyl-substituted quinolin 2-ones as anticancer agents)

RN 260050-74-6 CA
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-4-[3-[(trimethylsilyl)ethynyl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 34 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 132:194299 CA
TITLE: Preparation of quinolin-2-ones as anticancer agents
INVENTOR(S): Lyssikatos, Joseph Peter; La Greca, Susan Deborah; Yang, Bingwei Vera
PATENT ASSIGNEE(S): Pfizer Products Inc., USA; La Greca, Susan Deborah
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012498	A1	20000309	WO 1999-IB1393	19990805

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2341739	AA	20000309	CA 1999-2341739	19990805
AU 9949251	A1	20000321	AU 1999-49251	19990805
BR 9913315	A	20010522	BR 1999-13315	19990805
EP 1107962	A1	20010620	EP 1999-933080	19990805

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2002523503	T2	20020730	JP 2000-567526	19990805
JP 3494409	B2	20040209		
US 6495564	B1	20021217	US 1999-384339	19990826
PRIORITY APPLN. INFO.:			US 1998-98136P P	19980827
			WO 1999-IB1393 W	19990805

OTHER SOURCE(S): MARPAT 132:194299
GI

L7 ANSWER 34 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



I



II

AB The title compds. [I; R1 = H, alkyl, etc.; R2 = halo, CN, etc.; R3-R7 = H, alkyl, alkenyl, etc.; R8 = H, OR12, NR12R13, etc.; R9 = (CR13R14)t(imidazolyl) (wherein t = 0-5 and said imidazolyl moiety is optionally substituted by 1-2 R6 substituents); R10, R11 = R6; R12 = H, alkyl, alkenyl, etc.; R13, R14 = H, alkyl and where R13 and R14 are as (CR13R14)q or (CR13R14)t each is independently defined for each iteration of q or t in excess of 1], useful in the treatment of hyperproliferative disorders, such as cancer (no data), were prepd. E.g., prepn. of quinolin-2 one II , was given. Compds. I are effective at 0.01 10 mg/kg/day.

IT **260052-28-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of quinolin-2-ones as anticancer agents)

RN 260052-28-6 CA
CN Benzaldehyde, 3-[6 [(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1,2-dihydro-1-methyl 2-oxo-4-quinoliny1]- (9CI) (CA INDEX NAME)

L7 ANSWER 34 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 35 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(prenyltransferase inhibitor prepn. for treating diseases resulting
from heterotrimeric G protein membrane fixation)
RN 192185-89-0 CA
CN 2(1H)-Quinolinone,
4-(3 chlorophenyl)-6-[(4 chlorophenyl)hydroxy(1-methyl-
1H-imidazol-5 yl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 35 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 132:117561 CA
TITLE: Use of prenyltransferase inhibitors for preparing a medicine for treating pathologies resulting from heterotrimeric G protein membrane fixation
INVENTOR(S): Prevost, Gregoire; Lonchampt, Marie-Odile
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S, Fr.
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000002558 <--	A1	20000120	WO 1999-FR1611	19990705
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2780892 <--	A1	20000114	FR 1998-8730	19980708
FR 2780892	B1	20010817		
CA 2337261 <--	AA	20000120	CA 1999-2337261	19990705
AU 9946224 <--	A1	20000201	AU 1999-46224	19990705
EP 1094810 <--	A1	20010502	EP 1999-929396	19990705
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002520284	T2	20020709	JP 2000-558818	19990705
NO 2001000030 <--	A	20010108	NO 2001 30	20010103
PRIORITY APPLN. INFO.:			FR 1998-8730 A	19980708
			WO 1999-FR1611 W	19990705

OTHER SOURCE(S): MARPAT 132:117561
AB Prenyltransferase inhibitors are used for prepg. a medicine for treating pathologies resulting from prenylation of the .gamma. subunit of G protein. Said diseases comprise in particular diseases related to the following biol. functions or disorders: smell, taste, light perception, neurotransmission, neurodegeneration, endocrine and exocrine gland functioning, autocrine and paracrine regulation, blood pressure, embryogenesis, viral infection, immunol. functions, diabetes, and obesity.
IT **192185-89-0**

L7 ANSWER 36 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 132:90156 CA
TITLE: Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties, and use in treating cancer
INVENTOR(S): Van Ginckel, Robert Franciscus; Floren, Wim Joanna; End, David William; Wouters, Walter Boudewijn Leopold
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000001411 <--	A1	20000113	WO 1999-EP4545	19990630
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2336624 <--	AA	20000113	CA 1999-2336624	19990630
AU 9947805 <--	A1	20000124	AU 1999 47805	19990630
AU 762423	B2	20030626		
BR 9911861 <--	A	20010320	BR 1999-11861	19990630
EP 1094839 <--	A1	20010502	EP 1999-931229	19990630
EP 1094839	B1	20030502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 200000794	A	20020617	EE 2000-794	19990630
JP 2002519389	T2	20020702	JP 2000-557857	19990630
AT 238811	E	20030515	AT 1999-931229	19990630
PT 1094839	T	20030930	PT 1999-931229	19990630
ES 2199579	T3	20040216	ES 1999-931229	19990630
NZ 509646	A	20040227	NZ 1999-509646	19990630
HR 2000000903 <--	A1	20011231	HR 2000-903	20001228
BG 105108 <--	A	20011130	BG 2001-105108	20010103
US 6545020	B1	20030408	US 2001-743130	20010103
NO 2001000082 <--	A	20010105	NO 2001-82	20010105
ZA 2001000151	A	20020107	ZA 2001-151	20010105
HK 1034451	A1	20030905	HK 2001-105023	20010718
PRIORITY APPLN. INFO.:			EP 1998-202257 A	19980706
			EP 1998-204330 A	19981218
			EP 1998-204331 A	19981218

L7 ANSWER 36 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)
WO 1999-EP4545 W 19990630

OTHER SOURCE(S): MARPAT 132:90156
AB Farnesyl protein transferase inhibitors have radiosensitizing properties which makes them useful for prepg. a pharmaceutical compn. for administration before, during or after irradn. of a tumor for treating cancer in vivo .
IT **192185-51-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl protein transferase inhibitors with in vivo radiosensitizing properties, and use in treating cancer)
RN 192185-51-6 CA
CN 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 37 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 132:88171 CA
TITLE: Farnesyl protein transferase inhibitors for treating arthropathies
INVENTOR(S): End, David William; Cools, Marina Lucie Louise; Van Wauwe, Jean Pierre Frans
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000001386	A1	20000113	WO 1999-EP4546	19990630
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2337800	AA	20000113	CA 1999-2337800	19990630
AU 9947806	A1	20000124	AU 1999 47806	19990630
AU 762470	B2	20030626		
BR 9911869	A	20010327	BR 1999 11869	19990630
EP 1094815	A1	20010502	EP 1999-931230	19990630
EP 1094815	B1	20031112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200003882	T2	20010621	TR 2000-200003882	19990630
EE 200000770	A	20020415	EE 2000-770	19990630
JP 2002519379	T2	20020702	JP 2000-557832	19990630
AT 253914	E	20031115	AT 1999-931230	19990630
NZ 509647	A	20031219	NZ 1999-509647	19990630
PT 1094815	T	20040430	PT 1999-931230	19990630
ES 2212580	T3	20040716	ES 1999-931230	19990630
TW 557212	B	20031011	TW 1999 88111347	19990705
HR 2000000904	A1	20011231	HR 2000-904	20001228
BG 105110	A	20011130	BG 2001-105110	20010103
US 6451812	B1	20020917	US 2001-743077	20010103
NO 2001000053	A	20010302	NO 2001-53	20010104
ZA 2001000152	A	20020107	ZA 2001-152	20010105

L7 ANSWER 37 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)

HK 1034450	A1	20040305	HK 2001 105022	20010718
PRIORITY APPLN. INFO.:			EP 1998-202258 A	19980706
			WO 1999 EP4546 W	19990630

OTHER SOURCE(S): MARPAT 132:88171
AB Farnesyl protein transferase inhibitors are useful for prepg. a pharmaceutical compn. for treating arthropathies, e.g. rheumatoid arthritis, osteoarthritis, juvenile arthritis, and gout.
IT **192185-51-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl protein transferase inhibitors for treating arthropathies)
RN 192185-51-6 CA
CN 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 38 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 130:52420 CA
TITLE: (Imidazol-5-yl)methyl 2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
INVENTOR(S): End, David William; Zelesko, Michael J.
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9855124	A1	19981210	WO 1998-EP3182	19980525
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9880207	A1	19981221	AU 1998-80207	19980525
AU 740603	B2	20011108		
EP 988038	A1	20000329	EP 1998-928332	19980525
EP 988038	B1	20020814		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
BR 9810423	A	20001003	BR 1998-10423	19980525
TR 9902923	T2	20001121	TR 1999-9902923	19980525
JP 2002503235	T2	20020129	JP 1999-501440	19980525
NZ 501401	A	20020328	NZ 1998-501401	19980525
AT 222104	E	20020815	AT 1998-928332	19980525
ES 2182327	T3	20030301	ES 1998-928332	19980525
RU 2209066	C2	20030727	RU 2000-100032	19980525
ZA 9804700	A	19991201	ZA 1998-4700	19980601
US 6365600	B1	20020402	US 1999-445009	19991130
NO 9905883	A	20000202	NO 1999-5883	19991201
HK 1025046	A1	20021220	HK 2000-104198	20000708
US 2002091138	A1	20020711	US 2001-996147	20011128
US 6743805	B2	20040601		
US 2003229118	A1	20031211	US 2003-464570	20030618
US 6734194	B2	20040511		
US 2004157882	A1	20040812	US 2003-464702	20030618
PRIORITY APPLN. INFO.:			US 1997-47376P P	19970602
			WO 1998-EP3182 W	19980525
			US 1999-445009 A3	19991130
			US 2001-996147 A3	20011128

L7 ANSWER 38 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)
OTHER SOURCE(S): MARPAT 130:52420
GI



I



II

AB Title compds. I and their 3,4-dihydro derivs. [X = O, S; R = H, halogen, CN, alkyl, alkoxycarbonyl, (un)substituted Ph; R1, R2 = (un)substituted Ph; R3 = (un)substituted 4 imidazolyl; R4 = H, (un)substituted alkyl, CN, (un)substituted CO2H, imidazolyl, (un)substituted OH, SH, NH2; R5 = H, alkyl, alkoxy, halogen; R6 = H, alkyl; R7 = H, alkyl, aryl, aralkyl, quinolinylalkyl] were prepd. for use in inhibiting smooth muscle cell proliferation, e.g., in atherosclerosis or restenosis. Thus, the title compd. II was prepd. from 1-(N,N dimethylsulfamoyl)imidazole and the chlorobenzoylquinolinone in 5 steps. II had IC50 for inhibition of cell proliferation: A10 14, PASCM 24, CASCM 16 nM.

IT **192185-72-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (imidazol-5-yl)methyl 2-quinolinone derivs. as inhibitors of smooth muscle cell proliferation)

RN 192185-72-1 CA
CN 2(1H) Quinolinone, 6-[(R) amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L7 ANSWER 38 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 39 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 129:260460 CA
TITLE: Preparation of farnesyl transferase inhibiting 1,8-annelated quinolinones substituted with N- or C-linked imidazoles
INVENTOR(S): Venet, Marc Gaston; Angibaud, Patrick Rene; Ligny, Yannick Aime Eddy; Poncelet, Virginie Sophie; Sanz, Gerard Charles
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9840383 <--	A1	19980917	WO 1998-EP1296	19980303
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9870318 <--	A1	19980929	AU 1998-70318	19980303
AU 748702	B2	20020613		
EP 970079 <--	A1	20000112	EP 1998-916890	19980303
EP 970079	B1	20031001		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9808843 <--	A	20000704	BR 1998-8843	19980303
NZ 336234 <--	A	20001027	NZ 1998-336234	19980303
JP 2001515487 <--	T2	20010918	JP 1998-539193	19980303
RU 2204553	C2	20030520	RU 1999-121331	19980303
AT 251159	E	20031015	AT 1998-916890	19980303
CN 1128797	B	20031126	CN 1998-803064	19980303
IL 130362	A1	20040219	IL 1998-130362	19980303
SK 283927	B6	20040504	SK 1999-1217	19980303
ES 2209127	T3	20040616	ES 1998-916890	19980303
ZA 9801978 <--	A	19990909	ZA 1998-1978	19980309
NO 9904268 <--	A	19991108	NO 1999-4268	19990902
MX 9908307 <--	A	20000228	MX 1999-8307	19990909
US 6187786 <--	B1	20010213	US 1999-380856	19991220
HK 1024689	A1	20040305	HK 2000-103861	20000627

PRIORITY APPLN. INFO.: EP 1997-200708 A 19970310
EP 1997-200709 A 19970310

L7 ANSWER 39 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)
WO 1998-EP1296 A 19980303

OTHER SOURCE(S): MARPAT 129:260460
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; X = O, S; A = CH:CH, CH2CH2, CH2O, etc.; R1, R2 = H, OH, halo, etc.; when on adjacent positions R1 and R2 taken together may form OCH2O, OCH2CH2O, OCH:CH, etc.; R3, R4 = H, halo, CN, etc.; when on adjacent positions R3 and R4 taken together may form = OCH2O, OCH2CH2O, CH:CHCH:CH; R5 = (un)substituted imidazolyl; R6 = H, OH, halo, etc.] and their pharmaceutically acceptable acid addns. salts and the stereochem. isomeric forms, having farnesyl transferase inhibiting activity and useful in inhibiting tumor growth, were prepd. Thus, treatment of 1-methylimidazole with BuLi in THF followed by addn. of Et3SiCl, BuLi, and intermediate II afforded III which showed IC50 of 7.8 nM against farnesyl protein transferase.

IT **213389-54-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of farnesyl transferase inhibiting 1,8-annelated quinolinones substituted with N- or C-linked imidazoles)

RN 213389-54-9 CA
CN 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-8-methoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 40 OF 40 CA COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 127:95280 CA
TITLE: Preparation of farnesyl protein transferase-inhibiting (imidazol-5-yl)methyl-2-quinolinone anticancer agents
INVENTOR(S): Venet, Marc Gaston; Angibaud, Patrick Rene; Muller, Philippe; Sanz, Gerard Charles
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Neth.
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9721701	A1	19970619	WO 1996-EP4515	19961016
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, NO, NZ, PL, RO, SK, US, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
CA 2231105	AA	19970619	CA 1996-2231105	19961016
AU 9672948	A1	19970703	AU 1996-72948	19961016
AU 711142	B2	19991007		
EP 865440	A1	19980923	EP 1996-934727	19961016
EP 865440	B1	20020403		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 10511405	T2	19981104	JP 1996-521638	19961016
CN 1203598	A	19981230	CN 1996 198750	19961016
CN 1101392	B	20030212		
BR 9610745	A	19990713	BR 1996-10745	19961016
IL 123568	A1	20010808	IL 1996-123568	19961016
EE 3484	B1	20010815	EE 1998-146	19961016
EP 1162201	A2	20011212	EP 2001-202750	19961016
EP 1162201	A3	20031126		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 3257559	B2	20020218	JP 1997-521638	19961016
AT 215541	E	20020415	AT 1996-934727	19961016
PL 184171	B1	20020930	PL 1996-325962	19961016
PT 865440	T	20020930	PT 1996 934727	19961016
AP 1108	A	20021002	AP 1998-1257	19961016
W: GM, GH, KE, LS, MW, SD, SZ, UG, ZW				
ES 2175137	T3	20021116	ES 1996-934727	19961016

L7 ANSWER 40 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)

SK 283335	B6	20030603	SK 1998-704	19961016
CZ 293296	B6	20040317	CZ 1998-1573	19961016
TW 494101	B	20020711	TW 1996-85114832	19961130
ZA 9610254	A	19980605	ZA 1996 10254	19961205
HR 960576	B1	20020430	HR 1996-960576	19961205
NO 9800927	A	19980608	NO 1998 927	19980304
US 6037350	A	20000314	US 1998-84717	19980526
HK 1012188	A1	20020726	HK 1998-113364	19981215
US 6169096	B1	20010102	US 1999-363353	19990729
US 6420387	B1	20020716	US 2000-689211	20001012
PRIORITY APPLN. INFO.:			EP 1995-203427	A 19951208
			EP 1996-934727	A3 19961016
			WO 1996-EP4515	W 19961016
			US 1997-84717	A1 19970526
			US 1999-363353	A1 19990729

OTHER SOURCE(S): MARPAT 127:95280
GI



I



II

L7 ANSWER 40 OF 40 CA COPYRIGHT 2004 ACS on STN (Continued)

AB The title compds. [I; the dotted line represents an optional bond; X = O, S; R1 = H, (un)substituted alkyl, (un)substituted aryl, heterocyclylalkyl, etc.; R2, R3, R16 = H, hydroxy, halogen, cyano, alkyl, alkyloxy, hydroxyalkyloxy, etc.; R4, R5 = H, halogen, (un)substituted aryl, (un)substituted alkyl, NH2, etc.; R6, R7 = H, halogen, cyano, alkyl, 4,4-dimethyloxazolyl, etc.; R8 = H, alkyl, cyano, hydroxycarbonyl, alkyloxycarbonyl, etc.; R17 = H, halogen, cyano, alkyl, alkyloxycarbonyl, (un)substituted aryl; R18 = H, alkyl, alkyloxy, halogen; R19 = H, alkyl; etc.], which have farnesyl transferase-inhibiting activity, useful for the treatment of cancers, are prepd. and I-contg. formulations presented. Thus, imidazole deriv. II (m.p. >250.degree.) was prepd. and demonstrated a IC50 against human farnesyl protein transferase of 6.0 nM.

IT **192185-51-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone anticancer agents)

RN 192185-51-6 CA
CN 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl] 1 methyl- (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 13:52:19 ON 22 SEP 2004)

     FILE 'REGISTRY' ENTERED AT 13:52:28 ON 22 SEP 2004
L1                STRUCTURE UPLOADED
L2              0 S L1 SAM
L3              0 S L1 FULL
L4                STRUCTURE UPLOADED
L5            309 S L4 FULL

     FILE 'CA' ENTERED AT 13:55:39 ON 22 SEP 2004
L6            121 S L5
L7             40 S L6 AND PY<2002

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

STN INTERNATIONAL LOGOFF AT 13:56:35 ON 22 SEP 2004
```